scholarly journals Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (58) ◽  
pp. 97920-97927 ◽  
Author(s):  
Chan-Young Ock ◽  
Sehui Kim ◽  
Bhumsuk Keam ◽  
Soyeon Kim ◽  
Yong-Oon Ahn ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma

2018 ◽  
Vol 142 (6) ◽  
pp. 719-720
Author(s):  
Christine Kunkle ◽  
Flavia G Rosado
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Death Receptor ◽  
Neck Squamous Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

Context.— There has been increasing interest in understanding the role of programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway in cancer biology and its clinical significance in cancer therapy. Objective.— To discuss the studies of the PD-1/PD-L1 pathway in human papillomavirus–positive head and neck squamous cell carcinoma, focusing on the pathogenesis of cancer, characterization of the tumor microenvironment, and the effect of such studies in laboratory medicine. Data sources.— Data sources included peer-reviewed literature and reputable online sources. Conclusions.— To date, there are few studies of PD-1 and PD-L1 in human papillomavirus–positive head and neck squamous cell carcinoma. There is evidence that the PD-1/PD-L1 pathway has a role in this type of cancer; however, further studies are needed to better characterize the effect of the human papillomavirus and its use as a marker of therapy response.

Sign in / Sign up

Export Citation Format

Share Document